CTLA4 and nasopharyngeal carcinoma: In conclusion, the current study demonstrated that after failure of first-line platinum-based chemotherapy and second-line chemotherapy, some patients with advanced NPC may benefit from sequential anti-CTLA4 and anti-PD-1 immunotherapy.